Connect Biopharma Financials
| CNTB Stock | USD 1.02 0.01 0.97% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.74 | 4.9856 |
|
|
Investors should never underestimate Connect Biopharma's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Connect Biopharma's cash flow, debt, and profitability to make informed and accurate decisions about investing in Connect Biopharma Holdings.
Net Income |
|
Connect | Select Account or Indicator |
Understanding current and past Connect Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Connect Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Connect Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Connect Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Connect Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Connect Biopharma's management manipulating its earnings.
Connect Biopharma Stock Summary
Connect Biopharma competes with Assembly Biosciences, Instil Bio, CytomX Therapeutics, Achilles Therapeutics, and NextCure. Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US2075231017 |
| CUSIP | 207523101 |
| Location | China |
| Business Address | 12265 El Camino |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.connectbiopharm.com |
| Phone | 858 727 1040 |
| Currency | USD - US Dollar |
Connect Biopharma Key Financial Ratios
| Return On Equity | -0.18 | ||||
| Profit Margin | (0.89) % | ||||
| Operating Margin | 0.25 % | ||||
| Price To Sales | 2.36 X | ||||
| EBITDA | (58.37 M) |
Connect Biopharma Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 4.2M | 1.9M | 5.2M | 3.5M | 3.0M | 3.3M | |
| Retained Earnings | (292.1M) | (164.1M) | (373.4M) | (463.8M) | (539.3M) | (512.4M) | |
| Accounts Payable | 22.8M | 3.8M | 12.7M | 11.9M | 7.7M | 8.3M | |
| Net Receivables | 1.2M | 265.2K | 7.4M | 235.9K | 51K | 48.5K | |
| Total Current Assets | 362.8M | 161.9M | 275.4M | 158.5M | 121.0M | 203.4M |
Connect Biopharma Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 53K | 6.4K | 6.9K | 21.0K | 23K | 20.2K | |
| Ebit | (171.6M) | (118.4M) | (205.6M) | (112.3M) | (59.4M) | (62.3M) |
Connect Biopharma Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (2.3M) | 18.2M | 13.5M | (571.3M) | 75.2M | 78.9M | |
| Change In Cash | (92.6M) | 107.4M | 696.8M | (168.9M) | 27.0M | 25.6M | |
| Depreciation | 790K | 221.1K | 4.1M | 1.0M | 988K | 1.4M | |
| Capital Expenditures | 1.1M | 2.3M | 47.5M | 4.3M | 294K | 279.3K | |
| Net Income | (168.6M) | (119.4M) | (1.3B) | (116.1M) | (59.4M) | (62.4M) | |
| End Period Cash Flow | 309.0M | 154.7M | 1.7B | 80.4M | 106.0M | 100.7M |
Connect Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Connect Biopharma's current stock value. Our valuation model uses many indicators to compare Connect Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Connect Biopharma competition to find correlations between indicators driving Connect Biopharma's intrinsic value. More Info.Connect Biopharma Holdings is number one stock in return on equity category among its peers. It is rated second in return on asset category among its peers . At present, Connect Biopharma's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Connect Biopharma's earnings, one of the primary drivers of an investment's value.Connect Biopharma Systematic Risk
Connect Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Connect Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Connect Biopharma correlated with the market. If Beta is less than 0 Connect Biopharma generally moves in the opposite direction as compared to the market. If Connect Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Connect Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Connect Biopharma is generally in the same direction as the market. If Beta > 1 Connect Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Connect Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Connect Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Connect Biopharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Connect Biopharma November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Connect Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Connect Biopharma Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Connect Biopharma Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Connect Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Connect Biopharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 5.72 | |||
| Information Ratio | 0.0226 | |||
| Maximum Drawdown | 48.67 | |||
| Value At Risk | (9.01) | |||
| Potential Upside | 12.12 |
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |